EXHIBIT 22

Pages for Synthetic Biologics, Inc. (SYN, now Theriva) on finviz.com (August 17 and 24, 2018) and Yahoo Finance (August 10, 2022), as preserved by the Internet Archive

Nejmeh v. Theriva Biologics, Inc., No. 3:26-cv-00705-ART-CSD (D. Nev.)
Cited in the First Amended Verified Complaint, paragraph(s) 31

Source
Internet Archive (Wayback Machine) captures, printed October 18, 2026: (1) http://web.archive.org/web/20180817201141/https://finviz.com/quote.ashx?t=SYN, page 1 of 6, showing "Shs Outstand 141.96M" and "Market Cap 362.00M"; the price chart image on that page was loaded by the archive from a later date and is not part of the August 17, 2018 figures; (2) http://web.archive.org/web/20180824163339/https://finviz.com/quote.ashx?t=SYN, page 1 of 6, showing "Shs Outstand 127.16M" and "Market Cap 347.15M"; (3) http://web.archive.org/web/20220810220306/https://finance.yahoo.com/quote/SYN?ltr=1, all pages, showing "Market Cap 187.501M" at close of 1.4200. The remaining pages of the finviz captures are publicly available at the addresses shown.

The Wayback Machine - https://web.archive.org/web/20180817201141/https://finviz.com/quote.ashx?t=SYN
Your browser is no longer supported. Please, upgrade your browser.

Search ticker, company or pr

TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. ×

publish chart | save to portfolio | create alert **Type:** candle | line | **advanced** | interactive | perf **Timeframe:** intraday | **daily** | weekly Settings | monthly



SYN [NYSE]

Synthetic Biologics, Inc.

Healthcare | Biotechnology | USA


financial highlights | statements

Index	-	P/E	-	EPS (ttm)	0.00	Insider Own	0.43%	Shs Outstand	141.96M	Perf Week	-38.98%
Market Cap	362.00M	Forward P/E	-	EPS next Y	0.00	Insider Trans	0.00%	Shs Float	123.61M	Perf Month	-65.63%
Income	-0.10M	PEG	-	EPS next Q	-0.04	Inst Own	28.10%	Short Float	2.74%	Perf Quarter	-70.55%
Sales	-	P/S	-	EPS this Y	98.40%	Inst Trans	0.11%	Short Ratio	109.68	Perf Half Y	-82.35%
Book/sh	-0.05	P/B	-	EPS next Y	100.00%	ROA	-137.60%	Target Price	3.00	Perf Year	-87.65%
Cash/sh	0.05	P/C	50.99	EPS next 5Y	-	ROE	543.10%	52W Range	2.45 - 36.75	Perf YTD	-85.66%
Dividend	-	P/FCF	-	EPS past 5Y	60.70%	ROI	-	52W High	-92.51%	Beta	1.61
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	-	Gross Margin	-	52W Low	12.31%	ATR	0.72
Employees	24	Current Ratio	1.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	20.98	Volatility	28.58% 16.04%
Optionable	No	Debt/Eq	-	EPS Q/Q	4.50%	Profit Margin	-	Rel Volume	4.24	Prev Close	2.55
Shortable	No	LT Debt/Eq	-	Earnings	Aug 08 AMC	Payout	-	Avg Volume	30.86K	Price	2.75
Recom	2.00	SMA20	-45.86%	SMA50	-58.82%	SMA200	-79.16%	Volume	127,458	Change	7.90%

Jan-06-17	**Reiterated**	FBR & Co.	Outperform	$5 → $6
May-06-16	**Reiterated**	FBR Capital	Outperform	$10 → $9
Feb-26-16	**Initiated**	FBR Capital	Outperform	$10
Oct-13-15	**Initiated**	RBC Capital Mkts	Outperform	$8
Mar-16-15	**Downgrade**	Maxim Group	Buy → Hold	$3

The Wayback Machine - https://web.archive.org/web/20180824163339/https://finviz.com/quote.ashx?t=SYN
Your browser is no longer supported. Please, upgrade your browser.

TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. ×



SYN [NYSE]

Synthetic Biologics, Inc.

Healthcare | Biotechnology | USA

financial highlights | statements

Index	-	P/E	-	EPS (ttm)	-0.04	Insider Own	0.43%	Shs Outstand	127.16M	Perf Week	7.06%
Market Cap	347.15M	Forward P/E	8.40	EPS next Y	0.33	Insider Trans	0.00%	Shs Float	127.16M	Perf Month	-61.48%
Income	-0.10M	PEG	-	EPS next Q	-1.33	Inst Own	27.10%	Short Float	2.66%	Perf Quarter	-69.01%
Sales	-	P/S	-	EPS this Y	98.40%	Inst Trans	0.00%	Short Ratio	69.65	Perf Half Y	-79.47%
Book/sh	-1.76	P/B	-	EPS next Y	100.00%	ROA	-137.60%	Target Price	3.00	Perf Year	-86.93%
Cash/sh	0.06	P/C	48.89	EPS next 5Y	-	ROE	543.10%	52W Range	2.45 - 36.75	Perf YTD	-84.65%
Dividend	-	P/FCF	-	EPS past 5Y	60.70%	ROI	-	52W High	-92.92%	Beta	1.65
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	-	Gross Margin	-	52W Low	6.13%	ATR	0.59
Employees	24	Current Ratio	1.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	24.67	Volatility	12.76% 17.82%
Optionable	No	Debt/Eq	-	EPS Q/Q	4.50%	Profit Margin	-	Rel Volume	1.93	Prev Close	2.73
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 08 AMC	Payout	-	Avg Volume	48.59K	Price	2.60
Recom	2.00	SMA20	-35.21%	SMA50	-57.75%	SMA200	-79.37%	Volume	41,413	Change	-4.76%

Jan-06-17	**Reiterated**	FBR & Co.	Outperform	$5 → $6
May-06-16	**Reiterated**	FBR Capital	Outperform	$10 → $9
Feb-26-16	**Initiated**	FBR Capital	Outperform	$10
Oct-13-15	**Initiated**	RBC Capital Mkts	Outperform	$8
Mar-16-15	**Downgrade**	Maxim Group	Buy → Hold	$3

Synthetic Biologics, Inc. (SYN)

NYSE American - NYSE American Delayed Price. Currency in USD

Add to watchlist | Visitors trend 2W ↓ 10W ↑ 9M ↑ | Quote Lookup

1.4200 +0.0300 (+2.16%)
At close: 12:00PM EDT

1.4900 +0.07 (+4.93%)
After hours: 01:43PM EDT

Data Disclaimer Help Suggestions
Privacy Dashboard
Privacy About Our Ads Terms Sitemap
© 2022 Yahoo. All rights reserved.

Trade prices are not sourced from all markets

Chart Events
Neutral *pattern detected*
View all chart patterns

Performance Outlook

Short Term 2W - 6W	Mid Term 6W - 9M	Long Term 9M+

Previous Close	1.3900	Market Cap	187.501M
Open	1.4600	Beta (5Y Monthly)	1.55
Bid	1.4200 x 1200	PE Ratio (TTM)	N/A
Ask	1.4400 x 800	EPS (TTM)	-0.2240
Day's Range	1.3600 - 1.4900	Earnings Date	Mar 02, 2022 - Mar 07, 2022
52 Week Range	1.3500 - 5.6000	Forward Dividend & Yield	N/A (N/A)
Volume	334,987	Ex-Dividend Date	N/A
Avg. Volume	188,075	1y Target Est	16.25

All | News | Press Releases | Research Reports | SEC Filings

GlobeNewswire • 6 days ago

Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage...

Q4 Inc. Announces Appointment of Chief Financial...
Business Wire

Moody's Corporation Posted an Updated Management...
Business Wire

GlobeNewswire • 6 days ago

Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022...

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage...

Placement of Convertible Preferred Stock

ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc.. (NYSE American: SYN) ("Synthetic Biologics" or the...

GlobeNewswire • 26 days ago

Synthetic Biologics Announces Reverse Stock Split

ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage...

GlobeNewswire • 3 months ago

Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed...

Benzinga • 3 months ago

Synthetic Biologics Posts Encouraging Safety Data on SYN-020 In Healthy Volunteers

Synthetic Biologics Inc (NYSE: SYN) has announced safety data from its Phase 1 multiple ascending dose (MAD) trial of SYN-020...

GlobeNewswire • 3 months ago

Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1...

-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022...

GlobeNewswire • 3 months ago

Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operation...

ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage...

GlobeNewswire • 3 months ago

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology...

Scientific Advisory Board of leading experts in oncolytic adenoviruses and gene therapies strengthens transformative clinic...

GlobeNewswire • 3 months ago

Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed t...

- VCN-11 incorporates a proprietary albumin binding domain in the virus shell with the potential to improve systemic delivery and...